Long-term dynamics of epidemiological characteristics of some chronic leukemia and lymphoma in Moscow before, during and after the pandemic of the new coronavirus infection COVID-19. Epidemiologic study
- Authors: Vinogradova O.Y.1,2,3, Chernikov M.V.1, Neverova A.L.1, Kosenkova V.P.1, Kochkareva Y.B.1, Shikhbabaeva D.I.1, Pankrashkina M.M.1, Sharkunov N.N.1, Ptushkin V.V.1,2,3,4
-
Affiliations:
- Botkin Hospital
- Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology
- Pirogov Russian National Research Medical University
- Russian Medical Academy of Continuous Professional Education
- Issue: Vol 26, No 2 (2024)
- Pages: 149-158
- Section: Articles
- URL: https://journals.rcsi.science/1815-1434/article/view/260596
- DOI: https://doi.org/10.26442/18151434.2024.2.202776
- ID: 260596
Cite item
Full Text
Abstract
Background. The COVID-19 pandemic, which swept the world in 2020–2021, had a significant impact on the epidemiological picture of hematological malignancies.
Aim. To study the dynamics of epidemiological indicators of five chronic hemoblastoses in Moscow over a 12-year period, and also to assess the impact of the COVID-19 pandemic on these indicators.
Materials and methods. A population-based study was conducted for five types of oncohematological diseases: multiple myeloma, Hodgkin's lymphoma, follicular lymphoma, chronic lymphocytic leukemia, chronic myeloid leukemia. The annual rates of morbidity, mortality, prevalence of these nosologies, overall survival, and expected overall survival were calculated. Gender and age characteristics for each disease were determined.
Results and discussion. The present study showed a uniform increase in the incidence and prevalence of five hematological malignancies between 2012 and 2019. Convincing evidence of an increase in mortality and a decrease in the number of diagnosed cases in comparison with the expected figures for these hematological malignancies in 2020–2021 was presented. A greater reduction was shown for cases diagnosed at early stages compared to later ones. During the pandemic, a significant increase in mortality was recorded among patients with chronic lymphocytic leukemia and multiple myeloma, while in cohorts of patients with chronic myeloid leukemia and Hodgkin lymphoma it increased slightly. The return of morbidity, mortality and prevalence rates to the original dynamics in 2022–2023 has been demonstrated.
Conclusion. This study demonstrated the features of the regional pattern of incidence, mortality, prevalence and gender-age characteristics of five hematological malignancies and provided the changes in the indicators dynamics of different hematological malignancies during the COVID-19 pandemic.
Full Text
##article.viewOnOriginalSite##About the authors
Olga Yu. Vinogradova
Botkin Hospital; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University
Author for correspondence.
Email: olgavinz@mail.ru
ORCID iD: 0000-0002-3669-0141
D. Sci. (Med.), Botkin Hospital, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Pirogov Russian National Research Medical University
Russian Federation, Moscow; Moscow; MoscowMikhail V. Chernikov
Botkin Hospital
Email: mchernikov25@mail.ru
ORCID iD: 0000-0002-7869-209X
Res. Officer
Russian Federation, MoscowAnna L. Neverova
Botkin Hospital
Email: anyuta6549@yandex.ru
ORCID iD: 0000-0001-9524-7070
Cand. Sci. (Biol.)
Russian Federation, MoscowVictoria P. Kosenkova
Botkin Hospital
Email: kosenkowa.vik@yandex.ru
ORCID iD: 0009-0001-2974-4973
hematologist
Russian Federation, MoscowYulia B. Kochkareva
Botkin Hospital
Email: kochkareva_yulia@mail.ru
Cand. Sci. (Med.)
Russian Federation, MoscowDzhariiat I. Shikhbabaeva
Botkin Hospital
Email: djeri.shih@mail.ru
ORCID iD: 0000-0002-1384-1621
Cand. Sci. (Med.)
Russian Federation, MoscowMaria M. Pankrashkina
Botkin Hospital
Email: bobkowa.hematol@mail.ru
ORCID iD: 0000-0002-5658-9729
Cand. Sci. (Med.)
Russian Federation, MoscowNikolai N. Sharkunov
Botkin Hospital
Email: anyuta6549@yandex.ru
hematologist
Russian Federation, MoscowVadim V. Ptushkin
Botkin Hospital; Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology; Pirogov Russian National Research Medical University; Russian Medical Academy of Continuous Professional Education
Email: vadimvadim@inbox.ru
ORCID iD: 0000-0002-9368-6050
D. Sci. (Med.), Prof., Botkin Hospital, Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Pirogov Russian National Research Medical University, Russian Medical Academy of Continuous Professional Education
Russian Federation, Moscow; Moscow; Moscow; MoscowReferences
- Покровский В.И., Пак С.Г., Брико Н.И., Данилкин Б.К. Инфекционные болезни и эпидемиология: учебник. 2-е изд. М.: ГЭОТАР-Медиа, 2007 [Pokrovskii VI, Pak SG, Briko NI, Danilkin BK. Infektsionnye bolezni i epidemiologiia: uchebnik. 2-e izd. Moscow: GEOTAR-Media, 2007 (in Russian)].
- Макмахон Б., Трихопулос Д. Эпидемиология: принципы и методы. 2-е изд. Бостон: Литтл, Браун; 1996 [Makmakhon B, Trikhopulos D. Epidemiologia: printsipy i metody. 2-e izd. Boston: Littl, Braun; 1996 (in Russian)].
- Куликов С.М., Гармаева Т.Ц. Популяционные исследования в гематологии. Вестник последипломного медицинского образования. 2014;1:1-74 [Kulikov SM., Garmaieva TTs. Populiatsionnye issledovania v gematologii. Vestnik poslediplomnogo meditsinskogo obrazovaniia. 2014;1:1-74 (in Russian)].
- Bray F, Laversanne M, Sung H, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229-63. doi: 10.3322/caac.21834
- Pagano L, Salmanton-García J, Marchesi F, et al. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA). J Hematol Oncol. 2021;14(1):168. doi: 10.1186/s13045-021-01177-0
- Чуднова Т.С., Мисюрина Е.Н., Барях Е.А., и др. COVID-19 у пациентов с острыми лейкозами: опыт 3 лет пандемии. Онкогематология. 2023;18(4):45-52 [Chudnova TS, Misiurina EN, Bariakh EA, et al. COVID-19 in patients with acute leukemia: 3 years’ experience of pandemic. Oncohematology. 18(4):45-52 (in Russian)]. doi: 10.17650/1818-8346-2023-18-4(Suppl)-45-52
- Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391-405. doi: 10.1182/blood-2016-03-643544
- Виноградова О.Ю., Птушкин В.В., Черников М.В., и др. Эпидемиология множественной миеломы в городе Москве. Терапевтический архив. 2019;91(7):83-92 [Vinogradova OYu, Ptushkin VV, Chernikov MV, et al. Epidemiology of multiple myeloma in city Moscow. Terapevticheskii Arkhiv (Ter. Arkh.). 2019;91(7):83-9 (in Russian)]. doi: 10.26442/00403660.2019.07.000305
- Sant M, Allemani C, Tereanu C, et al. Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE project. Blood. 2010;116(19):3724-34. doi: 10.1182/blood-2010-05-282632
- Blimark CH, Turesson I, Genell A, et al. Swedish Myeloma Registry. Outcome and survival of myeloma patients diagnosed 2008-2015. Real world data on 4904 patients from the Swedish Myeloma Registry (SMR). Haematologica. 2018;103(3):506-13. doi: 10.3324/haematol.2017.178103
- Chen Y, Wang H, Kantarjian H, et al. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk Lymphoma. 2013;54(7):1411-7. doi: 10.3109/10428194.2012.745525
- Rafiq M, Hayward A, Warren-Gash C, et al. Socioeconomic deprivation and regional variation in Hodgkin’s lymphoma incidence in the UK: a population-based cohort study of 10 million individuals. BMJ Open. 2019;9(9):e029228. doi: 10.1136/bmjopen-2019-029228
- Li Y, Wang Y, Wang Z, et al. Racial differences in three major NHL subtypes: descriptive epidemiology. Cancer Epidemiol. 2015;39(1):8-13. doi: 10.1016/j.canep.2014.12.001
- Siegel R, DeSantis C, Virgo K, et al. Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 2012;62(4):220-41. doi: 10.3322/caac.21149
- Волкова С.А., Ковалишена О.В., Гостюжова Е.А., и др. Эффект от терапии иматинибом по данным клинико-эпидемиологического мониторинга хронического миелолейкоза в Нижегородской области за период 2000–2010 г. Гематология и трансфузиология. 2011;4:17-9 [Volkova SA, Kovalishena OV, Gostyuzhova EA, et al. Effekt ot terapii imatinibom po dannym kliniko-epidemiologicheskogo monitoringa khronicheskogo myeloleikoza v nizhegorodskoi oblasti za period 2000–2010 g. Gematologiia i transfuziologiia. 2011;4:17-9 (in Russian)].
- Лучинин А.С., Семочкин С.В., Минаева Н.В., и др. Эпидемиология множественной миеломы по данным анализа популяционного регистра Кировской области. Онкогематология. 2017;12(3):50-6 [Luchinin AS, Semochkin SV, Minaeva NV, et al. Epidemiology of multiple myeloma according to the Kirov region population registers. Oncohematology. 2017;12(3):50-6 (in Russian)]. doi: 10.17650/1818-8346-2017-12-3-50-56
- Войцеховский В.В., Ландышев Ю.С., Есенина Т.В., и др. Эпидемиология онкогематологических заболеваний в Амурской области. Амурский медицинский журнал. 2014;3(7):61-6 [Voytsehovskiy VV, Landyshev YuS, Esenina TV, et al. Epidemiology of hematologic malignancies in the Amur region. Amur Medical Journal. 2014;3(7):61-6 (in Russian)].
- Поспелова Т.И., Березина О.В., Ковынев И.Б., и др. Хронический лимфолейкоз в г. Новосибирске: реальная клиническая практика. Бюллетень медицинской науки. 2021;3(23):66-72 [Pospelova TI, Berezina OV, Kovynev IB, et al. Chronic lymphocytic leukemia: Novosibirsk real clinical practice. Bulletin of Medical Science. 2021;3(23):66-72 (in Russian)]. doi: 10.31684/25418475_2021_3_66
- Зверев А.М., Ружникова А.А., Левит М.Л., Бурдаева О.Н. Эпидемиология лимфомы Ходжкина и неходжкинских лимфом в Архангельской области за период с 2000 по 2009 г. Гематология и трансфузиология. 2014;59(1-S1):95 [Zverev AM, Ruzhnikova AA, Levit ML, Burdaeva ON. Epidemiologiya limfomy Hodzhkina i nekhodzhkinskih limfom v Arhangel'skoi oblasti za period s 2000 po 2009 g. Gematologiia i transfuziologiia. 2014;59(1-S1):95(in Russian)].
- Solovev MV, Mendeleeva LP, Pokrovskaya OS, et al. Epidemiology and Clinical Characteristics of Patients with Multiple Myeloma. Results of a Prospective Multicenter Study in Russian Federation. Blood. 2015;126:4248.
- Shanbhag S, Ambinder RF. Hodgkin lymphoma: A review and update on recent progress. CA Cancer J Clin. 2018;68(2):116-32. doi: 10.3322/caac.21438
- Junlén HR, Peterson S, Kimby E, et al. Follicular lymphoma in Sweden: nationwide improved survival in the rituximab era, particularly in elderly women: a Swedish Lymphoma Registry study. Leukemia. 2015;29(3):668-76. doi: 10.1038/leu.2014.251
- Куликов С.М., Виноградова О.Ю., Челышева Е.Ю., и др. Заболеваемость хроническим миелолейкозом в 6 регионах России по данным популяционного исследования 2009-2012 гг. Терапевтический архив. 2014;86(7):24-30 [Kulikov SM, Vinogradova OIu, Chelysheva EIu, et al. Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study. Terapevticheskii Arkhiv (Ter. Arkh.). 2014;86(7):2430 (in Russian)].
- Becker N. Epidemiology of multiple myeloma. Recent Results Cancer Res. 2011;183:25-35. doi: 10.1007/978-3-540-85772-3_2
- Multiple myeloma epidemiology and demographics Ed. CM Gibson, H Allaham. 2018.
- National cancer institute (2015). Available at: http://www.cancer.gov/types/myeloma/hp/myeloma-treatment-pdq#cit/section_1.1. Accessed: 20.09.2015.
- Hoffmann VS, Baccarani M, Hasford J, et al. The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries. Leukemia. 2015;29(6):1336-43. doi: 10.1038/leu.2015.73
- Batlevi CL, Sha F, Alperovich A, et al. Follicular lymphoma in the modern era: survival, treatment outcomes, and identification of high-risk subgroups. Blood Cancer J. 2020;10:74. doi: 10.1038/s41408-020-00340-z
- Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-49. doi: 10.3322/caac.21660
- Витрина статистических данных. Численность постоянного населения. Режим доступа: https://showdata.gks.ru/report/278928/ Ссылка активна на 12.01.2024 [Showcase of statistical data. Resident population. Available at: https://showdata.gks.ru/report/278928/ Accessed: 12.01.2024 (in Russian)].
- Бутуханова И.С., Жалсанова Э.Б., Алексеева А.Н., и др. Анализ заболеваемости множественной миеломой в Республике Бурятия. Современные проблемы науки и образования. 2016;4 [Butukhanova IS, Zhalsanova EB, Alekseyeva AN, et al. Analiz zabolevaiemosti mnozhestvennoi mielomoi v Respublike Buriatiia. Sovremennyie problemy nauki i obrazovaniia. 2016;4 (in Russian)].
- National Cancer Institute Surveillanse, Epidemiology, and End Results. Cancer Stat Facts: Leukemia- Chronic Lymphocytic Leukemia (CLL). Available at: https://seer.cancer.gov/statfacts/html/clyl.html.2020. Accessed: 14.12.2023.
- Cerhan JR. Epidemiology of Follicular Lymphoma. Hematol Oncol Clin North Am. 2020;34(4):631-46. doi: 10.1016/j.hoc.2020.02.001
- Teras LR, DeSantis CE, Cerhan JR, et al. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J Clin. 2016;66(6):443-59. doi: 10.3322/caac.21357
- Sasaki K, Haddad FG, Short NJ, et al. Outcome of Philadelphia chromosome-posi- tive chronic myeloid leukemia in the United States since the introduction of imatinib therapy – The Surveillance, Epidemiology, and End Results database, 2000-2019. Cancer. 2023;129(23):3805-14. doi: 10.1002/cncr.35038
- Negoita S, Chen HS, Sanchez PV, et al. Annual Report to the Nation on the Status of Cancer, part 2: Early assessment of the COVID-19 pandemic’s impact on cancer diagnosis. Cancer. 2024;130(1):117-27. doi: 10.1002/cncr.35026
- El-Ashwah S, Salmanton-García J, Bilgin YM, et al. The mortality of COVID-19 in CML patients from 2020 until 2022: results from the EPICOVIDEHA survey. Leuk Lymphoma. 2024;65(2):199-208. doi: 10.1080/10428194.2023.2280886
- Vijenthira A, Gong IY, Fox TA, et al. Outcomes of patients with hematologic malignancies and COVID-19: a systematic review and meta-analysis of 3377 patients. Blood. 2020;136(25):2881-92. doi: 10.1182/blood.2020008824
- Mato AR, Roeker LE, Lamanna N, et al. Outcomes of COVID19 in patients with CLL: a multicenter international experience. Blood. 2020;136(10):1134-43. doi: 10.1182/blood.2020006965
- Galimberti S, Petrini M, Baratè C, et al. Tyrosine kinase inhibitors play an antiviral action in patients affected by chronic myeloid leukemia: a possible model supporting their use in the fight against SARS-CoV-2. Front Oncol. 2020;10:1428. doi: 10.3389/fonc.2020.01428